


VIAL et al.
Appl. No. 10/521,329
Atty. Ref.: 2350-102
Amendment After Final Rejection
June 24, 2010

AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:


Claims 1-52. (Cancelled)

53. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically effective amount of at least one compound having a ~~general~~ formula (I)



in which

X represents a group of formula (II)



where Z is a $-(\text{CH}_2)_m$ group, with $m = 8$ to 21,

$n = 0$ or 1

and $\text{Y} = \text{R}_3$,

VIAL et al.
Appl. No. 10/521,329
Atty. Ref.: 2350-102
Amendment After Final Rejection
June 24, 2010

R_1 and R'_1 , identical to or different from one another, being chosen from H, alkyl, OH, O-alkyl, O-aryl, O-CO-alkyl, O-CO-aryl, OSO_2 -alkyl, OSO_2 -aryl, OSO_2 -heterocycle, O-CO-S-alkyl, O-CO-NH-alkyl, O-CO-O-alkyl, O-CO-O-aryl, O-CO-S-aryl, O-CO-NH-aryl, $PO(O\text{-alkyl})_2$, $PO(O\text{-aryl})_2$, CO-O- CH_2 -aryl, or cycloalkyl,

R_2 and R'_2 , identical to or different from one another, being chosen from H, alkyl, CO-O- CH_2 -aryl, CO-O-alkyl, or cycloalkyl,

R_3 and R'_3 , identical to or different from one another, representing H, alkyl, CO-O-aryl, $COO\text{-}CH(R)\text{-}O\text{-}CO\text{-}alkyl$, $PO(O\text{-alkyl})_2$, $PO(O\text{-aryl})_2$, $PO(ONa)_2$, or CO-O- $CH(R)$ -aryl,

R being H or alkyl,

and

R_1 and R_2 , and/or R'_1 and R'_2 , or R_2 and R_3 and/or R'_2 and R'_3 , or R_1 , R_2 and R_3 and/or R'_1 , R'_2 and R'_3 , together form a nitrogenated mono heterocycle with the nitrogen atom or atoms to which they are respectively attached, or also,

R_2 and R_3 and/or R'_2 and R'_3 can be the same substituents or different, [[or]] double-bonded to the nitrogen, [[or]] cyclized with, respectively, R_1 or R'_1 in order to form a heterocycle, if appropriate and R_2 , R_3 , R'_2 and R'_3 may be independently substituted by R_a , which is chosen from H, alkyl, alkyl substituted by 1, 2 or 3 halogen atoms, aryl, CO-O-alkyl, CO-O-aryl, -CO-OH, -CO-NH₂, -CN, -CO-NH-alkyl, -CO-NH-aryl, -CO-N-(alkyl)₂, CO-nitrogenated heterocycle, CO-oxygenated heterocycle, CO-

VIAL et al.
Appl. No. 10/521,329
Atty. Ref.: 2350-102
Amendment After Final Rejection
June 24, 2010

nitrogenated and oxygenated heterocycle, NH₂, NH-alkyl, N(alkyl)₂, nitrogenated heterocycle, oxygenated heterocycle, nitrogenated and oxygenated –heterocycle, -O-alkyl, -O-aryl, -O-CH₂-aryl, CH₂NH₂, CH₂NH-alkyl, CH₂N-dialkyl, CH₂NH-aryl, CH₂-nitrogenated heterocycle, CH₂-oxygenated heterocycle, CH₂-nitrogenated and oxygenated heterocycle, CH₂-CO-OH,

or a pharmacologically acceptable salt thereof,

in association with an inert pharmaceutical vehicle,

with the proviso that when R₁ and R₂ form a heterocycle, and R'₁ and R'₂ form the same heterocycle as is formed with R₁ and R₂, and n=0, and R₃ is hydrogen or alkyl, and R'₃ is hydrogen or alkyl, or

when R₁ and R₃ form a heterocycle, and R'₁ and R'₃ form the same heterocycle as is formed with R₁ and R₃, and n=0, and R₂ is hydrogen or alkyl, and R'₂ is hydrogen or alkyl,

then m is 12-21.


54. (Previously Presented) The pharmaceutical composition according to claim 53, in a form administrable by oral route, by injectable route, or by rectal route.

Claims 55-57. (Cancelled)

58. (Currently Amended) The pharmaceutical composition of claim [[55]]53 for ~~the treatment of wherein said infectious disease is malaria.~~

59. (Previously Presented) A pharmaceutical composition according to claim 53
wherein the pharmaceutically effective amount is an amount effective to treat malaria.

60. (Currently Amended) A pharmaceutical composition according to claim 53
wherein said at least one compound has the ~~general~~ formula (V)



or a pharmacologically acceptable salt thereof.

61. (Previously Presented) A pharmaceutical composition according to claim 60
wherein in said compound or pharmacologically acceptable salt thereof R_1 , R'_1 , R_2 , R'_2 ,
 R_3 and R'_3 are independent of one another.

62. (Previously Presented) A pharmaceutical composition according to claim 61,
wherein in said compound or pharmacologically acceptable salt thereof R_1 and/or R'_1 do
not represent a hydrogen atom, whilst R_3 and/or R'_3 , R_2 and/or R'_2 , represent a
hydrogen atom.

63. (Previously Presented) A pharmaceutical composition according to claim 62,
wherein in said compound or pharmacologically acceptable salt thereof R_1 and/or R'_1 ,
and R_2 and/or R'_2 represent a hydrogen atom, whilst R_3 and/or R'_3 are different from a
hydrogen atom.

64. (Previously Presented) A pharmaceutical composition according to claim 60, wherein in said compound or pharmacologically acceptable salt thereof

R_1 and R_2 , and/or R'_1 and R'_2 , or


R_2 and R_3 , and/or R'_2 and R'_3 , or

R_1 , R_2 and R_3 and/or R'_1 , R'_2 and R'_3 together form a heterocycle.

65. (Previously Presented) A pharmaceutical composition according to claim 64, wherein in said compound or pharmacologically acceptable salt thereof


R_1 and R_2 as well as R'_1 and R'_2 form a heterocycle, having the general formula

(VI)



66. (Previously Presented) A pharmaceutical composition according to claim 65, wherein in said compound or pharmacologically acceptable salt thereof R_1 and/or R'_1 represent a hydrogen atom, and R_2 and R_3 , and/or R'_2 and/or R'_3 represent a $-(CH_2)_p-$ group, wherein p is an integer from 1 to 5.

67. (Previously Presented) A pharmaceutical composition according to claim 53, wherein in said compound or pharmacologically acceptable salt thereof R₂ and R₃ and/or R'₂ and R'₃ form a same substituent and form together with R₁ or respectively R'₁ a bis-oxadiazole of formula (VIII.)



68. (Previously Presented) A pharmaceutical composition according to any one of claims 60-67, in a form administrable by oral route, by injectable route, or by rectal route.

69. (Previously Presented) A pharmaceutical composition of any one of claims 53, 54 or 60-67, wherein the pharmaceutically effective amount is an amount effective to treat malaria.